• Find people
• Intranet

News

24/01/2023 - Institutional news

The Carlos III Health Institute awards a grant of almost five million euros to the CORDELIA research project, led by the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar)

The CORDELIA project, spearheaded by Dr. Jaume Marrugat, a researcher at the Hospital del Mar Medical Research Institute, coordinator of the Girona Heart Registry Group (REGICOR) and coordinator of the Cardiovascular Epidemiology Programme of the CIBER on Cardiovascular Diseases (CIBERCV), has received almost five million euros in the Precision Personalised Medicine Research call under the Strategic Health Action Plan 2021-2023, in the framework of the strategic projects for economic recovery and transformation (PERTE) for cutting-edge health, with the help of the European funds from the Recovery, Transformation and Resilience Plan. This grant, awarded by the Carlos III Health Institute, will enable the complete genome of more than 101,000 people to be analysed in order to determine the genetic risk of suffering certain cardiovascular diseases.

Working meeting of CORDELIA project researchers

This work is the third most highly funded of those selected in this call for proposals and the project that will receive the most money in Catalonia. Using data from the participants in the CORDELIA cohort (Collaborative cOhorts Reassembled Data to Study mEchanisms and Longterm Incidence of chronic diseAses), the relationship between the complete genome of the volunteers and the incidence of coronary and cardiovascular disease over a ten-year period in people who initially did not have cardiovascular disease will be assessed. It is the first time that a project of this kind will be carried out in southern Europe, with the data coming from 31 cohorts in 23 institutions across 12 autonomous communities.

Researchers of the REGICOR group

This will involve the complete genotyping of 101,397 people from the CORDELIA cohort. "A unique opportunity to take advantage of a set of population cohorts that already have an average follow-up time of over eleven years. A set of 84 standardised common variables has already been collected from the participants, including information on risk factors", explains Dr. Marrugat, who adds that "Genotyping their complete genome will make it possible to immediately determine the genetic characteristics associated with the appearance of coronary heart disease during the follow-up period." This will clarify some of the unanswered questions about how genetics is associated with these pathologies in our region.

The aim of this work is to progress towards personalised medicine by improving the precision of procedures for preventing coronary and cardiovascular disease by introducing an assessment of the genetic characteristics associated with these conditions. It will thereby provide a new tool for supporting individualised decisions on the use of the available pharmacological and lifestyle resources. The study will last three years.

More news